Arbutus Biopharma (ABUS) Return on Equity ROE from the second quarter 2026 to second quarter 2025 and annually, average high and low, overall ranking from Jun 30 2026 to Jun 30 2025 - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Arbutus Biopharma Corp  (NASDAQ: ABUS)

Arbutus Biopharma's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics


What is ROE for Arbutus Biopharma in the second quarter 2026?
Arbutus Biopharma Corp achieved a return on average equity (ROE) of 106.04 % in its second quarter 2026, this is above ABUS's average return on equity of -69.27%.
Arbutus Biopharma Corp shareholder's equity over the 12 months ending in its second quarter 2026 are valued at $144 million

ROE decreased relative to the period ending , due to the decline in net income.

Within the Major Pharmaceutical Preparations industry 7 other companies had a higher return on equity. While return on equity, the total ranking has deteriorated compared to the first quarter 2026 from 35 to 49.

What is ROE?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Equity (Jun 30 2026)
II. Quarter		 (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter		 (Jun 30 2025)
II. Quarter
Y / Y Equity Change 324.69 % 238.72 % -21.35 % -29.75 % -
Y / Y Net Income Change - - - - -
Net Income (TTM) in Millions 153 161 -34 -112 -124
Return On Equity (TTM) 106.04 % 169.38 % -54.01 % -166.89 % -169.84 %
ABUS's Total Ranking # 49 # 35 # 3154 # 2628 #
Equity (TTM) in Millions 259 186 77 56 61
Seq. Equity Change 38.76 % 143.51 % 37.79 % -8.78 % 10.67 %
Seq. Net Income Change - - - - -

Back to ABUS Management Effectiveness >> ABUS's 5 Years Annual ROE >> Compare ABUS ROE to its Competitors
Return On Equity Company Ranking
Within: No.
Industry # 8
Sector # 17
Overall # 49

Return On Equity Statistics
High Average Low
169.38 %
-69.27 %
-229.1 %
(Mar 31 2026)   (Jun 30 2020)





ABUS Annual Return On Equity (Dec 31 2025)
2025		 (Dec 31 2024)
2024		 (Dec 31 2023)
2023		 (Dec 31 2022)
2022		 (Dec 31 2021)
2021
Total Equity in Millions 77 97 106 137 169
Y / Y Equity Change -21.35 % -8.16 % -22.53 % -19.23 % 66.17 %
Net Income in Millions -34 -140 -73 -4 -76
Y / Y Net Income Change - - - - -
Return On Equity -43.75 % -143.62 % -68.71 % -3.25 % -45 %

Back to ABUS Management Effectiveness >> ABUS's 5 Years Annual ROE >> Compare ABUS ROE to its Competitors




More Return On Equity Ratios
Major Pharmaceutical Preparations Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
ABUS's' Return on Equity at Yahoo Finance
ABUS's Roe Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for ABUS's Competitors
Subscribers only: Roe for Arbutus Biopharma's Suppliers
Subscribers only: Return On Equity for ABUS's Customers




Companies with similar Return On Equity at Jun 30 2026, within Healthcare Sector ROE
Meiragtx Holdings Plc  283.67 %
Silexion Therapeutics Corp  276.59 %
Actinium Pharmaceuticals Inc  213.46 %
Halozyme Therapeutics Inc   180.63 %
Capforce Inc   168.50 %
Aveanna Healthcare Holdings Inc   150.35 %
Liquidia Corporation  149.64 %
Interpace Biosciences Inc   142.98 %
Oncotelic Therapeutics Inc   124.17 %
Fortress Biotech Inc   118.22 %
Medpace Holdings Inc   110.15 %
Pulmatrix Inc   108.83 %
Arbutus Biopharma Corp  106.04 %
Rigel Pharmaceuticals Inc  96.49 %
Exelixis Inc   93.62 %
Alnylam Pharmaceuticals Inc   93.61 %
Eli Lilly And Company  92.54 %
Amgen Inc   89.32 %
Q32 Bio Inc   76.88 %
3m Company  76.55 %
Oramed Pharmaceuticals Inc  73.03 %
Tg Therapeutics Inc   72.30 %
Idexx Laboratories Inc  71.96 %
Elite Pharmaceuticals Inc   71.10 %
Zoetis Inc   68.87 %
Rallybio Corporation  68.56 %
Earth Science Tech Inc   66.17 %
Aurinia Pharmaceuticals Inc   59.00 %
Vaxart Inc   53.04 %
Qhslab Inc   51.21 %

Date modified: 2026-09-26T07:10:45+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.